SCHEMBL22719935

SCHEMBL22719935

Cc1ccc(Br)cc1Oc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR2A P28223 9/20 0.42
SLC6A4 P31645 9/20 0.42
KCNH2 Q12809 9/20 0.42
EPAS1 Q99814 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL47039 0.89 MAPT (0.43) MEN1ALDH1A1MAPTHPGDKMT2A
SCHEMBL15354404 0.85 HTR2A (0.54) KDM4EMEN1ALDH1A1CYP1A2CYP2D6
SCHEMBL806363 0.81 SLC6A4 (0.50) ALDH1A1SLC6A4MAOB
SCHEMBL29504939 0.78 ALDH1A1 (0.43) KDM4EALDH1A1CYP1A2MAPTCYP2C9
SCHEMBL22719576 0.78 ALDH1A1 (0.43) KDM4EALDH1A1CYP1A2MAPTCYP2C9
SCHEMBL9272342 0.78 MAPT (0.50) KDM4EMEN1ALDH1A1CYP1A2CYP2D6
SCHEMBL10828215 0.76 HTR2A (0.48) KDM4EMEN1ALDH1A1CYP1A2CYP2D6
SCHEMBL22732034 0.76 HTR2A (0.46) KDM4EMEN1ALDH1A1CYP1A2CYP2D6
SCHEMBL12726142 0.76 KMT2A (0.47) ALDH1A1MAPTKMT2ASMN1; SMN2MAOA
SCHEMBL7176771 0.75 TTR (0.49) KDM4EMEN1ALDH1A1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11925651-B2 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-03-12 US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 US disclosed
US-11458149-B1 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-10-04 US disclosed
CN-114502540-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2022-05-13 CN disclosed
EP-3976192-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-04-06 EP disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 WO disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 KDM4E 972/4885MEN1 3307/4885ALDH1A1 1195/4885
US-11925651-B2 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 KDM4E 972/4885MEN1 3307/4885ALDH1A1 1195/4885
US-11458149-B1 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 KDM4E 972/4885MEN1 3307/4885ALDH1A1 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.